4/15
09:00 am
kzia
Novogen (KZIA) is now covered by Laidlaw. They set a "buy" rating and a $25.00 price target on the stock.
Medium
Report
Novogen (KZIA) is now covered by Laidlaw. They set a "buy" rating and a $25.00 price target on the stock.
4/15
08:16 am
kzia
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform [TheStreet.com]
Medium
Report
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform [TheStreet.com]
4/15
08:00 am
kzia
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
Medium
Report
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
4/13
05:37 pm
kzia
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform [Yahoo! Finance]
Low
Report
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform [Yahoo! Finance]
4/13
05:18 pm
kzia
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform [TheStreet.com]
Low
Report
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform [TheStreet.com]
4/13
05:05 pm
kzia
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
Medium
Report
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
3/8
01:31 am
kzia
Low
Report
1/30
09:07 am
kzia
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) [Yahoo! Finance]
Medium
Report
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) [Yahoo! Finance]
1/30
08:00 am
kzia
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Medium
Report
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
1/28
08:41 am
kzia
Novogen (NASDAQ:KZIA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Medium
Report
Novogen (NASDAQ:KZIA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
1/27
08:00 am
kzia
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
High
Report
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
1/24
05:09 am
kzia
Novogen (NASDAQ:KZIA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Novogen (NASDAQ:KZIA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.